Dr. Mohit Trikha, PhD

President & COO at Kivu Biosciences

Panellist

Dr. Mohit (Mo) Trikha is the President and COO of Kivu Bioscience. He brings over 25 years of drug development expertise in oncology. He has been instrumental in advancing more than 40 programs from target identification to clinical trials in oncology. Previously, Mo was a venture partner at Apple Tree Partners, and also led oncology early development at AbbVie, where he oversaw the development of discovery-stage programs to clinical proof of concept, focusing on ADCs, bispecifics, and CAR-T therapies. He has contributed to the development of key drugs such as Kadcyla, Polivy, and vismodegib, and chaired collaborations with leading institutions like TeneoBio, Calibr, and The Scripps Research Institute. Earlier in his career, he held roles at Genentech, Centocor/Johnson & Johnson, and Triphase Accelerator. Mo earned his B.S. in Biochemistry from California State University, Los Angeles, and his PhD in Biochemistry and Molecular Biology from the University of Southern California.